Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as DR-3001
Oxybutinyn Vaginal Ring · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Oxybutinyn Vaginal Ring 4mg | EXPERIMENTAL | inserted daily and replaced every 4 weeks |
| Oxybutinyn Vaginal Ring 6mg | EXPERIMENTAL | inserted daily and replaced every 4 weeks |
| Name | Type | Description |
|---|---|---|
| DR-3001 | DRUG | 4mg/day vaginal ring inserted vaginally and replaced every 4 weeks |
| Placebo | DRUG | Placebo vaginal ring inserted vaginally and replaced every 4 weeks |
| Oxybutinyn Vaginal Ring 4mg | DRUG | - |
| Oxybutinyn Vaginal Ring 6mg | DRUG | - |
Inclusion Criteria: * Women 18 years of age or older, ambulatory, with a history and presentation consistent with urge incontinence ≥ 6 months * Able to distinguish between stress and urge incontinence * During the Screening Period able to demonstrate the presence of overactive bladder with urge in...
Oxybutinyn Vaginal Ring is an investigational small molecule therapy being developed for overactive bladder. It is a vaginal ring formulation designed to deliver oxybutynin, and it is also known as Oxybutinyn Vaginal Ring 4mg. It is currently in Phase 3 clinical development.
Oxybutinyn Vaginal Ring is being developed for the treatment of overactive bladder. The clinical program enrolled adult women aged 18 years and older with this condition. It is an investigational product and has not been established as a marketed treatment.
Oxybutinyn Vaginal Ring is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the sponsor of the clinical program evaluating this vaginal ring formulation for overactive bladder.
Oxybutinyn Vaginal Ring is in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently active. The drug remains investigational and is not approved for commercial use.
Oxybutinyn Vaginal Ring has been studied in one completed Phase 3 trial, NCT00782769, titled A Safety Extension Study of DR-OXY-301. The trial enrolled 240 participants in the United States, was randomized, double blind, and controlled, and included adult women aged 18 years and older with overactive bladder.